Superbug Treatments
The Future of Medicine
Superbug Treatments
The Future of Medicine
The Future of Medicine
The Future of Medicine
Drug resistant bacteria are now a leading global health risk. Click here and here to learn more. By 2050, a human being may die every 3 seconds and we will lose $100 trillion dollars in global GDP. This is an existential threat to humanity. The solution to this deadly threat may be hidden in plain view...
In 2007, researchers at the Mayo Clinic were studying a new medical device. They were startled when they discovered that the sound waves emitted from the device were able to destroy four of the most dangerous types of antibiotic resistant bacteria (superbugs).
How Does it Work?
Microorganisms have protective shells and walls that are critical to their survival. These shells can be ruptured with a patented application of sound waves. Once these shells are ruptured, the microorganism can be destroyed.
Click here to learn more about the Mayo Clinic Study. A follow up study was conducted in 2010 at Winston-Salem State University to confirm these findings. Click here to learn more.
Conclusions:
Although this medical device was designed to treat and heal chronic wounds, researchers at the Mayo Clinic were startled when they discovered an unexpected benefit: destruction of antibiotic resistant bacteria.
Scanning and transmission electron micrographs of methicillin-resistant Staphylococcus aureus during the control and experimental periods (× 40,000). Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007
Scanning and transmission electron micrographs of vancomycin-resistant enterococci during
the control and experimental periods (× 40,000). Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007
Scanning and transmission electron micrographs of Pseudomonas aeruginosa during the
control and experimental periods (× 40,000). Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007
Scanning electron micrographs of Staphylococcus aureus during the control and experimental periods (× 40,000). Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007
FDA approved medical device directs focused sound waves to wound beds. During a feasibility study, scientists discover an unexpected benefit. The sound waves are able to destroy drug resistant bacteria. Remarkably, this discovery goes unnoticed.
In the summer of 1928, a young Scottish physician named Alexander Fleming was in such a rush to go on vacation that he left a stack of dirty petri dishes in his sink. The dishes were smeared with dangerous bacteria. When Dr. Fleming returned from his vacation, he found something astonishing. One of the petri dishes was dotted with bacteria everywhere except one spot where some mold had been growing. The area around it was clear, as if protected by an unseen barrier. Dr. Fleming realized that the mold had secreted a liquid that killed several strands of the bacteria. Remarkably, this discovery was ignored for 13 years, hidden in plain view. It wasn’t until 1941, when this extraordinary finding led to the creation of the world’s first antibiotic, Penicillin. This discovery changed the course of history.
Destroying drug resistant bacteria with sound waves. With this new breakthrough, we are on the verge of the next medical revolution. Join us. Together we can save lives, create value, and change medicine forever.
Eliaz P. Babaev is the Co-Founder of Arobella Medical, LLC. CEO and President. Co-founder of Celleration Inc. (former CTO and CEO). Former Head of Biomedical Engineering Laboratory State Technical University, Baku. Ph.D. in Biomechanical Engineering and Moscow-Bauman Technical University. D.Sc. (Doctor of Science), Biomedical Engine
Eliaz P. Babaev is the Co-Founder of Arobella Medical, LLC. CEO and President. Co-founder of Celleration Inc. (former CTO and CEO). Former Head of Biomedical Engineering Laboratory State Technical University, Baku. Ph.D. in Biomechanical Engineering and Moscow-Bauman Technical University. D.Sc. (Doctor of Science), Biomedical Engineering (Medical Ultrasound) in 1993 and D.Sc., Biomedical Instrumentations and Biomechanics from Latvian Academy of Science, Center For Biomechanics & Biomedical Engineering Riga, Latvia in 1991. He received B.S. and M.S. Degree in Mechanical Engineering (Industrial Ultrasound - NDT for Oil Reservoirs) in Azerbaijan Technical University Baku, Azerbaijan in 1969. Dr. Babaev has more than 40+ years expertise in Non-Imaging Medical Ultrasound and particularly in Ultrasound Wound Management, live tissue repair and in all the areas of advances in skin, wound care, nursing, tissue science, drug delivery systems, wound treatment technologies, tissue engineering, and body architectonics research and cancer research including apoptosis. 50+ US and 100+ Worldwide Patents are issued, numerous are pending, 50+ scientific articles, abstracts are published. Learn More
Michael R. Afremov is a co-Founder and Chairman of the Board of Directors of Arobella Medical, LLC. An active member of Minnesota’s growing medical device industry, he is dedicated to developing advanced medical technologies.
Before Arobella, Mr. Afremov was a partner of AGA Medical Corporation, which he co-founded in 1995. Mr. Afremov was
Michael R. Afremov is a co-Founder and Chairman of the Board of Directors of Arobella Medical, LLC. An active member of Minnesota’s growing medical device industry, he is dedicated to developing advanced medical technologies.
Before Arobella, Mr. Afremov was a partner of AGA Medical Corporation, which he co-founded in 1995. Mr. Afremov was instrumental in the research and development of a septal occluder that allowed septal defects (commonly called “hole in the heart”) to be repaired with minimally invasive procedures, eliminating the need for major open-heart surgery.
Prior to AGA Medical, Mr. Afremov spent 12 years working in product development, manufacturing and quality control positions with companies such as Biomedicus (Medtronic), Flexmedics Corporation, Novell Biomedical and Microvena Corporation.
Mr. Afremov is also co-Founder and Chairman of the Board of AB Ortho, LLC and Arobella Medical, LLC; and is the President & CEO of Minnesota Medical Development, Inc. He has made major philanthropic contributions to different charities, including largest donation ever to the Children’s Hospitals and Clinics of Minnesota.
Born in Saint Petersburg, Mr. Afremov immigrated to the United States in 1983 and enjoys spending time with family, practicing kung fu, and is an enthusiast of military history. Learn More
Rudy Boschwitz is a former United States Senator from Minnesota. He is also a former United States Ambassador to the United Nations Commission on Human Rights. He was President George H.W. Bush's emissary to Ethiopia in 1991. His mission resulted in Operation Solomon, the rescue of the small Black Jewish community of Ethiopia and their
Rudy Boschwitz is a former United States Senator from Minnesota. He is also a former United States Ambassador to the United Nations Commission on Human Rights. He was President George H.W. Bush's emissary to Ethiopia in 1991. His mission resulted in Operation Solomon, the rescue of the small Black Jewish community of Ethiopia and their dramatic airlift to Israel. The negotiations also helped cause a simultaneous end to the decades-long civil war in Ethiopia. In a Rose Garden ceremony in June 1991, President Bush awarded Senator Boschwitz the Citizen's Medal for his achievements in the Horn of Africa. Boschwitz attended Johns Hopkins University and New York University, where he received his law degree. He has served on the boards of many organizations, including the Chicago Mercantile Exchange, the American Cancer Society, Twin City Federal Financial Corporation, the American-Israeli Public Affairs Committee, IDT Corporation and the Friends of the World Food Program. He also served on the Board of Directors of the Jewish Institute for National Security Affairs; has been an AIPAC Board Member; and is a member of the Council on Foreign Relations. Learn More.
Blake Vanderhyde, Esq. is the President of Vanderhyde Consulting, Inc. His primary focus is helping advance meaningful technologies that will create new markets and disrupt existing ones. His expertise centers around strategic thinking, accelerating growth, and developing actionable plans for long-term success in a rapidly changing worl
Blake Vanderhyde, Esq. is the President of Vanderhyde Consulting, Inc. His primary focus is helping advance meaningful technologies that will create new markets and disrupt existing ones. His expertise centers around strategic thinking, accelerating growth, and developing actionable plans for long-term success in a rapidly changing world. He is also the Founder of Vanderhyde Law. Blake graduated Summa Cum Laude from Saint Cloud State University in Minnesota. and from the William Mitchell College of Law, where he was a member of the Law Review. He is admitted in State and Federal Court and has been recognized by various organizations including Super Lawyers, and Minnesota Law and Politics Who’s Who. Past and/or current memberships include: American Association for Justice, Minnesota Association for Justice, Minnesota State Bar Association, Hennepin County Bar Association, Delta Theta Phi Law Fraternity International, and the American Inns of Court, Minnesota – Douglas K. Amdahl Inn. Learn More.
Copyright © 2024 Superbug Treatments - The Future of Medicine - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.